Up to $175 million! Reding Pharmaceuticals will receive exclusive rights to the "first-in-class" therapy in Greater China

On January 7, Reding Pharmaceuticals issued a press release saying it would receive argenx's exclusive development and commercial rights to the new drug efgartigimod in Greater China, including Chinese mainland, Hong Kong, Taiwan and Macau, for a total of $175 million in co-payments.
press release, efgartigimod's first adaptive systemic severe muscle weakness has been filed for listing in the United States.
Efgartigimod is a "first-in-class" therapy that targets FcRn and is designed to reduce pathogenic IgG antibodies and block the IgG recirculation process.
FcRn binds are designed to prevent degradation of IgG, so by preventing the binding of IgG to FcRn, IgG antibodies that mediate autoimmune diseases are depleted more quickly, thereby reducing the symptoms of the disease. according to
, the product can treat autoimmune diseases known to be driven by pathogenic IgG antibodies, including severe muscle weakness (MG), common herpes (PV), immunocompytic platelet reduction (ITP), chronic inflammatory demyelinative multiple neuropathy (CIDP) and so on.
May 2020, efgartigimod reached the end of its main study in ADAPT, a critical Phase 3 clinical trial for patients with anti-acetylcholine(AChR) antibody-positive systemic severe muscle weakness (gMG).
data showed that 67.7% of AChR antibody-positive patients treated with efgartigimod met the treatment standard (vs 29.7%) for the main study endpoint.
Efgartigimod reaches the main research endpoint of the ADAPT trial (Photo source: Resources 2) Under the terms of the agreement, Reding Pharmaceuticals will be responsible for the global registered clinical research and development of efgartigimod multiple adaptive disorders in China, as well as the launch of phase 2 validation studies on multiple new adaptations in Greater China to accelerate the development of more autoimmune adaptations of efgartigimod worldwide.
, Argenx will receive the equivalent of $75 million in Reding Pharmaceuticals stock as an advance and $100 million in recent milestones and other payments.
, founder, chairman and chief executive officer of Efgartigimod, said that efgartigimod is developing a variety of immunodeficirations that are in urgent need of new treatment options.
expect to bring this "first-in-class" product to a wide range of Chinese patients.